Abstract
Peptidylarginine deaminase 4 (PAD4) is a crucial post-translational modifying enzyme catalyzing the conversion of arginine into citrulline residues, and mediating the formation of neutrophil extracellular traps (NETs). PAD4 plays a vital role in the occurrence and development of cardiovascular diseases, autoimmune diseases, and various tumors. Therefore, PAD4 is considered as a promising drug target for disease diagnosis and treatment. More and more efforts are devoted to developing highly efficient and selective PAD4 inhibitors via high-throughput screening, structure-based drug design and structure-activity relationship study. This article outlined the physiological and pathological functions of PAD4, and corresponding representative small molecule inhibitors reported in recent years.
| Original language | English |
|---|---|
| Article number | 113840 |
| Number of pages | 11 |
| Journal | European Journal of Medicinal Chemistry |
| Volume | 226 |
| Early online date | 9 Sept 2021 |
| DOIs | |
| Publication status | Published - 15 Dec 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
User-Defined Keywords
- Autoimmune disease
- Citrullination
- Histone
- NETs
- PAD4 inhibitor
Fingerprint
Dive into the research topics of 'Peptidylarginine deiminases 4 as a promising target in drug discovery'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver